<DOC>
	<DOCNO>NCT01015144</DOCNO>
	<brief_summary>The aim study assess influence atorvastatin select indicator inflammatory condition , function leave ventricle factor affect occurrence undesired event like rehospitalizations mortality patient dilate cardiomyopathy .</brief_summary>
	<brief_title>The Influence Atorvastatin Parameters Inflammation Function Left Ventricle</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>patient 18 year old old patient sign informed consent patient dilate cardiomyopathy ( accord ESC 2007 ) patient significant coronary artery stenoses &gt; 30 % cardiac catheterization BP â‰¥140/90 lub &lt; 90/60 congenital heart disease acquire valvular disease except mitral incompetence secondary leave ventricular dilatation New York Heart Association ( NYHA ) functional class IV statin treatment preserve hyperactivity aminotransferase unexplained etiology , muscle disorder might cause druginduced myopathy , uncontrolled diabetes , liver disease , creatinine level &gt; 2 mg/dl and/or GFR &lt; 30ml/min , abuse alcohol drug , chronic inflammatory disease , pregnancy lactation , severe hypothyroidism , immunosuppressive treatment , operation severe injury last month vaccination last 3 month heart stimulation device implantable cardioverter defibrillator n't write conscious consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>atorvastatin</keyword>
	<keyword>dilate cardiomyopathy</keyword>
	<keyword>heart failure</keyword>
	<keyword>inflammation</keyword>
</DOC>